NCT02545283: A reported trial by Hoffmann-La Roche
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02545283 |
|---|---|
| Title | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 30, 2015 |
| Completion date | April 24, 2020 |
| Required reporting date | April 24, 2021, midnight |
| Actual reporting date | April 22, 2021 |
| Date last checked at ClinicalTrials.gov | July 16, 2025 |
| Days late | None |